Moneycontrol PRO
HomeNewsBusinessStocksAlkem Laboratories shares fall 2.02% in Wednesday's trading session

Alkem Laboratories shares fall 2.02% in Wednesday's trading session

The stock is trading on the Nifty Midcap 150 index.

August 06, 2025 / 10:32 IST
Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Shares of Alkem Laboratories declined by 2.02% to trade at Rs 4,821.50 in Wednesday's session. The stock is a constituent of the Nifty Midcap 150 index.

In related corporate actions, the company has scheduled a conference call on August 12, 2025, at 4:30 p.m. to discuss the Q1 FY26 financial results. Additionally, a board meeting is scheduled for August 12, 2025, to consider and approve the standalone and consolidated unaudited financial results for the quarter ending June 30, 2025.

Recent Financial Performance:

Alkem Laboratories' recent financial performance shows the following trends based on consolidated quarterly data:

  • Revenue: The company's revenue has fluctuated over the past five quarters, with a recent figure of Rs 3,143.75 Crore for the quarter-ending March 2025.
  • Net Profit: Net profit also varied, with Rs 323.01 Crore reported for the quarter-ending March 2025.
  • EPS: Earnings per share stood at Rs 25.57 for the quarter-ending March 2025.
HeadingMar 2024Jun 2024Sep 2024Dec 2024Mar 2025
RevenueRs 2,935.82 CroreRs 3,031.82 CroreRs 3,414.67 CroreRs 3,374.28 CroreRs 3,143.75 Crore
Net ProfitRs 304.48 CroreRs 550.24 CroreRs 701.96 CroreRs 640.79 CroreRs 323.01 Crore
EPS24.5545.6057.6052.3425.57
Annual Consolidated Financials:

The yearly financial performance provides the following insights:

  • Revenue: There has been a steady increase in revenue over the years, with Rs 12,964.52 Crore reported for the year-ending March 2025.
  • Net Profit: Net profit has also increased, reaching Rs 2,216.00 Crore for the year-ending March 2025.
  • EPS: The Earnings Per Share (EPS) has risen to Rs 181.11 for the year-ending March 2025.
Heading20212022202320242025
RevenueRs 8,865.01 CroreRs 10,634.19 CroreRs 11,599.26 CroreRs 12,667.58 CroreRs 12,964.52 Crore
Net ProfitRs 1,617.77 CroreRs 1,680.32 CroreRs 1,006.81 CroreRs 1,811.46 CroreRs 2,216.00 Crore
EPS132.57137.6382.31150.19181.11
BVPS632.20740.05789.21896.231,002.50
ROE21.4819.0510.8817.4118.06
Debt to Equity0.230.300.140.120.09

The revenue for the year ending March 2025 increased by 2.34% compared to the year ending March 2024. Net profit for the year ending March 2025 also increased by 22.33% compared to the previous year.

Alkem Laboratories announced a final dividend of Rs 8 per share (400%) with an effective date of August 8, 2025. Prior to this, an interim dividend of Rs 37 per share (1850%) was announced on January 28, 2025, with an effective date of February 14, 2025.

The stock is trading on the Nifty Midcap 150 index.

Alpha Desk
first published: Aug 6, 2025 10:32 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347